RT Journal Article
SR Electronic
T1 ▼ Sacubitril valsartan for heart failure
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 66
OP 69
DO 10.1136/dtb.2016.6.0405
VO 54
IS 6
YR 2016
UL http://dtb.bmj.com/content/54/6/66.abstract
AB ▼ Sacubitril valsartan (Entresto—Novartis) is a new oral drug licensed for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction.1 It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan.1-3 Here, we review the evidence for sacubitril valsartan and consider its place in the management of heart failure.